Krystal Biotech shares are trading higher after Stifel maintained a Buy rating and raised its price target to $220.
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech shares rose following Stifel's decision to maintain a Buy rating and increase the price target to $220.
September 11, 2024 | 6:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech shares are trading higher after Stifel maintained a Buy rating and raised its price target to $220.
The increase in price target and maintained Buy rating by Stifel is a positive signal to investors, likely boosting short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100